Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
255 hedge funds and large institutions have $7.36B invested in Cidara Therapeutics in 2025 Q4 according to their latest regulatory filings, with 139 funds opening new positions, 63 increasing their positions, 46 reducing their positions, and 55 closing their positions.
153% more first-time investments, than exits
New positions opened: 139 | Existing positions closed: 55
136% more capital invested
Capital invested by funds: $3.11B → $7.36B (+$4.25B)
100% more funds holding in top 10
Funds holding in top 10: 14 → 28 (+14)
63% more call options, than puts
Call options by funds: $496M | Put options by funds: $305M
47% more funds holding
Funds holding: 173 → 255 (+82)
37% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 46
22.17% less ownership
Funds ownership: 128.16% → 105.98% (-22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$204M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$203M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$126M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$105M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$97.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$289M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$215M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$135M |
| 4 |
VA
VR Adviser
New York
|
-$90.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.9M |
CDTX Hedge Fund Activity: Q4 2025 in Review
255 of the 8,263 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2025, worth a combined $7.36B — up 136% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 139 funds opened new CDTX positions and 55 closed out — a net gain of 84 holders — while 63 added to existing stakes and 46 trimmed.
The largest buyer was HBK Investments, opening a new position worth an estimated $204M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $289M sold.
- 255 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2025, up from 173 in Q3 2025.
- Funds reported $7.36B of Cidara Therapeutics stock for Q4 2025, up 136% quarter-over-quarter.
- 139 funds opened new Cidara Therapeutics positions in Q4 2025 and 55 closed out, a net change of +84 holders.
- The largest Cidara Therapeutics buyer in Q4 2025 was HBK Investments, an estimated $204M added.
- The largest Cidara Therapeutics seller in Q4 2025 was Bain Capital Life Sciences Investors, an estimated $289M sold.
Based on aggregated 13F filings for Q4 2025.